单次mRNA免疫可增强由SARS-CoV-2感染引发的交叉变异中和抗体。
A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.
作者信息
Stamatatos Leonidas, Czartoski Julie, Wan Yu-Hsin, Homad Leah J, Rubin Vanessa, Glantz Hayley, Neradilek Moni, Seydoux Emilie, Jennewein Madeleine F, MacCamy Anna J, Feng Junli, Mize Gregory, De Rosa Stephen C, Finzi Andrés, Lemos Maria P, Cohen Kristen W, Moodie Zoe, McElrath M Juliana, McGuire Andrew T
机构信息
Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, WA, USA.
Department of Global Health, University of Washington, Seattle, WA, USA.
出版信息
medRxiv. 2021 Mar 10:2021.02.05.21251182. doi: 10.1101/2021.02.05.21251182.
Emerging SARS-CoV-2 variants have raised concerns about resistance to neutralizing antibodies elicited by previous infection or vaccination. We examined whether sera from recovered and naive donors collected prior to, and following immunizations with existing mRNA vaccines, could neutralize the Wuhan-Hu-1 and B.1.351 variants. Pre-vaccination sera from recovered donors neutralized Wuhan-Hu-1 and sporadically neutralized B.1.351, but a single immunization boosted neutralizing titers against all variants and SARS-CoV-1 by up to 1000-fold. Neutralization was due to antibodies targeting the receptor binding domain and was not boosted by a second immunization. Immunization of naïve donors also elicited cross-neutralizing responses, but at lower titers. Our study highlights the importance of vaccinating both uninfected and previously infected persons to elicit cross-variant neutralizing antibodies.
新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体引发了人们对先前感染或疫苗接种所诱导的中和抗体耐药性的担忧。我们检测了康复者和未感染者在接种现有信使核糖核酸（mRNA）疫苗之前和之后采集的血清是否能够中和武汉-胡-1（Wuhan-Hu-1）和B.1.351变体。康复者接种疫苗前的血清能够中和武汉-胡-1，偶尔也能中和B.1.351，但单次免疫可使针对所有变体和严重急性呼吸综合征冠状病毒1（SARS-CoV-1）的中和效价提高多达1000倍。中和作用归因于靶向受体结合域的抗体，第二次免疫并未增强这种作用。对未感染者的免疫也引发了交叉中和反应，但效价较低。我们的研究强调了对未感染者和先前感染者进行疫苗接种以诱导交叉变体中和抗体的重要性。
Zotero 插件